For the quarter ending 2026-03-31, BRTX had $1,601,491 increase in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -2,154,405 | -3,207,636 | -3,038,277 | -7,996,062 |
| Depreciation and amortization | 52,394 | 52,836 | 52,620 | 104,529 |
| Dividend and interest income | 6,064 | 34,695 | 59,336 | 176,542 |
| Stock-based compensation | 290,215 | 447,860 | 399,932 | 2,477,834 |
| Change in fair value of warrant liabilities | 1,220,121 | 568,966 | 612,064 | -59,528 |
| Accounts receivable | -2,200 | 2,100 | -1,600 | -173,400 |
| Prepaid expenses and other current assets | 25,938 | -82,777 | 2,366 | -21,359 |
| Lease liability | - | - | - | 0 |
| Non-cash lease expense | - | - | - | 0 |
| Deferred revenue | - | - | - | 0 |
| Accounts payable | -682,003 | 482,455 | 230,209 | 126,861 |
| Gain on exchange of warrants | - | - | - | 0 |
| Accrued expenses and other current liabilities | -64,070 | 332,296 | 126,545 | -263,560 |
| Net cash used in operating activities | -3,807,792 | -2,415,173 | -2,901,137 | -5,472,653 |
| Sale of marketable securities | 1,043,367 | 2,480,343 | 2,548,105 | 6,664,238 |
| Purchases of equipment | - | 79,669 | 0 | 36,400 |
| Purchase of marketable securities | 74,920 | 0 | 550,467 | 2,128,680 |
| Net cash provided by investing activities | 968,447 | 2,400,674 | 1,997,638 | 4,499,158 |
| Exercise of stock options | - | -1,246 | 0 | 42,411 |
| Proceeds from issuance of common stock for cash | - | 1,085,000 | 0 | 2,011,250 |
| Proceeds from issuance of common stock and pre-funded warrants in registered direct offering | 5,000,000 | - | - | - |
| Payment of issuance costs | 559,164 | 105,148 | 0 | 72,805 |
| Proceeds from exchange and issuance of warrants, net | - | - | - | 0 |
| Payment of deferred offering costs | - | 50,665 | 49,308 | 0 |
| Repayment of financed insurance premiums | - | 4,698 | - | - |
| Net cash provided by financing activities | 4,440,836 | 923,243 | -49,308 | 1,980,856 |
| Net increase in cash and cash equivalents | 1,601,491 | 908,744 | -952,807 | 1,007,361 |
| Cash and cash equivalents - beginning of the period | 1,511,188 | 602,444 | 547,890 | - |
| Cash and cash equivalents - end of the period | 3,112,679 | 1,511,188 | 602,444 | - |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)